Biomarkers comprising peptide sequence vnhvtlsqpk for diagnosing alzheimer's disease
CA 2745724 C · Owner: Bayer Schering Pharma Aktiengesellschaft · Inventors: Sanchez, Jean-Charles; Yalkinoglu, Oezkan; Carrette, Odile
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method for assessing the state of Alzheimer's disease in patients is disclosed. A method , for monitoring the progression of Alzheimer's disease in patients is also disclosed. The , method applies detection of specific markers in body fluids (e.g. CSF) using , mass , spectrometric analysis (SELDI-TOF MS). The specific markers are polypeptides having , the sequence of VNHVTLSQPK.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 11, 2003 and granted June 2, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 11, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 11, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.